Stockscreener 앱 받기
33.68
9.39%
-3.49
시장 영업 전:
32.75
-0.93
-2.76%
전일 마감가:
$37.17
열려 있는:
$36.66
하루 거래량:
15.46M
Relative Volume:
0.66
시가총액:
$7.80B
수익:
$2.35B
순이익/손실:
$128.37M
주가수익비율:
64.51
EPS:
0.5221
순현금흐름:
$57.42M
1주 성능:
-4.99%
1개월 성능:
+7.02%
6개월 성능:
+7.33%
1년 성능:
-35.04%
1일 변동 폭
$33.58
$37.70
1주일 범위
$33.18
$37.70
52주 변동 폭
$13.74
$70.43
Hims Hers Health Inc Stock (HIMS) Company Profile
명칭
Hims Hers Health Inc
전화
415-851-0195
주소
2269 CHESTNUT ST, SAN FRANCISCO
Compare HIMS vs TAK, HLN, TEVA, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
33.68 | 7.80B | 2.35B | 128.37M | 57.42M | 0.5221 |
TAK
Takeda Pharmaceutical Co Adr
|
16.73 | 53.43B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
10.11 | 44.52B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.22 | 37.52B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
76.91 | 32.24B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
529.05 | 22.46B | 3.17B | 1.29B | 1.01B | 27.09 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-24 | 개시 | JP Morgan | Overweight |
| 2026-03-10 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2026-03-10 | 업그레이드 | Citigroup | Sell → Neutral |
| 2026-03-09 | 업그레이드 | Needham | Hold → Buy |
| 2026-02-24 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2026-01-12 | 개시 | Evercore ISI | In-line |
| 2025-12-09 | 개시 | Barclays | Overweight |
| 2025-10-21 | 개시 | KeyBanc Capital Markets | Sector Weight |
| 2025-06-23 | 다운그레이드 | Needham | Buy → Hold |
| 2025-06-04 | 재확인 | Needham | Buy |
| 2025-04-29 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2025-02-18 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2025-01-07 | 개시 | BTIG Research | Buy |
| 2024-12-17 | 개시 | Morgan Stanley | Overweight |
| 2024-11-14 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2024-08-22 | 개시 | Needham | Buy |
| 2024-08-09 | 다운그레이드 | Imperial Capital | Outperform → In-line |
| 2024-05-22 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-04-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-04-10 | 개시 | Canaccord Genuity | Buy |
| 2024-02-28 | 업그레이드 | Imperial Capital | In-line → Outperform |
| 2024-02-26 | 개시 | Leerink Partners | Market Perform |
| 2023-12-07 | 개시 | Imperial Capital | In-line |
| 2023-07-28 | 개시 | TD Cowen | Outperform |
| 2023-04-11 | 개시 | Robert W. Baird | Neutral |
| 2023-02-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-11-08 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-11-08 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | 개시 | Truist | Hold |
| 2022-07-15 | 개시 | SVB Leerink | Underperform |
| 2022-04-14 | 개시 | Guggenheim | Buy |
| 2022-04-01 | 재개 | Credit Suisse | Outperform |
| 2022-03-10 | 개시 | Deutsche Bank | Hold |
| 2021-12-02 | 개시 | Jefferies | Hold |
| 2021-11-11 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | 개시 | BofA Securities | Neutral |
| 2021-05-20 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | 개시 | Truist | Hold |
| 2021-03-09 | 개시 | Credit Suisse | Neutral |
| 2021-03-02 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-02-17 | 개시 | Citigroup | Neutral |
| 2021-02-12 | 개시 | Piper Sandler | Neutral |
| 2021-02-08 | 개시 | Tigress Financial | Buy |
모두보기
Hims Hers Health Inc 주식(HIMS)의 최신 뉴스
Hims & Hers Health, Inc. (HIMS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Hims & Hers Health Inc (CHIX:82Wd) Stock Price, Trades & News - GuruFocus
Hims & Hers Health (NYSE:HIMS): What Is Driving Attention? - Kalkine Media
This Trade Offers Two Ways To Profit From Hims & Hers Stock - Investor's Business Daily
2026-07-16 | Hims & Hers Health, Inc. (HIMS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation | NYSE:HIMS | Press Release - Stockhouse
Breakout attempt at $39.02 resistance. Can Hims & Hers Health stock extend gains? - Traders Union
A Look at Hims & Hers Health Inc (HIMS) After 5.8% Gain -- GF Va - GuruFocus
Law firm investigates Hims & Hers for allegedly sharing users' private health data without consent. - Pluang
Lowey Dannenberg, P.C. Investigates Hims & Hers Health, Inc. for Alleged Tracking of User Data - GlobeNewswire
Lowey Dannenberg, P.C. Investigates Hims & Hers Health, Inc. for Alleged Tracking of User Data - GlobeNewswire Inc.
Why is Hims & Hers Health stock up 6.1% today? - Traders Union
Hims & Hers Health shares gain more than 5% after price action confirms trend alignment above key moving averages - Traders Union
Why is Hims & Hers Health stock up today? Resistance test in focus for HIMS - Traders Union
Hims & Hers Health, Inc. (HIMS) Outpaces Stock Market Gains: What You Should Know - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Hims & Hers to announce Q2 2026 results on August 10 - scanx.trade
Is most-watched stock Hims & Hers Health, Inc. (HIMS) worth betting on now? - MSN
Hims & Hers to Announce Second Quarter 2026 Financial Results on August 10, 2026 - HIMS Investor Relations
HIMS Stock Logs Worst Week In 2 Months — Turns To Peptides Campaign Ahead Of Key FDA Meeting - Stocktwits
Is Most-Watched Stock Hims & Hers Health, Inc. (HIMS) Worth Betting on Now? - Yahoo Finance
Why Is HIMS Stock Slipping Premarket Today? - Stocktwits
Hims & Hers Names Dr. Anant Vinjamoori as Chief Medical Officer of Hims - AOL.com
A Look at Hims & Hers Health Inc (HIMS) After 3.0% Decline -- GF Value $39.29 vs Price $34.38 - GuruFocus
Why Hims & Hers Health Shares Are Falling Today - Quiver Quantitative
Hims & Hers Health Stock (HIMS) Opinions on Recent Technical Breakouts and Growth Prospects - Quiver Quantitative
Investor relations - HIMS Investor Relations
HIMS Stock Rises Overnight: CEO Shrugs Off Wild Swings, Bets On ‘Gold Standard’ Of Healthcare Over Next Decade - Stocktwits
HIMS Stock Under Pressure: BofA Warns Wegovy Churn Could Threaten Its Big H2 EBITDA Ramp - Stocktwits
HIMS Stock Hits 2026 High After Unlocking $400M Working Capital Through JPMorgan — Retail Gets Less Bearish - Stocktwits
Hims & Hers Health (HIMS) Draws GLP 1 Attention, Is The Valuation Already Too Rich? - simplywall.st
$Hims & Hers Health (HIMS.US)$ Why Wall Street is watching $HIMS beyond this quarter’s earnings - Moomoo
Truist reiterates Hold on Hims and Hers stock, $23 target on peptide uncertainty - Investing.com
Hims & Hers (HIMS) Stock Jumps 45% — Can This Momentum Continue? - Blockonomi
HIMS Maintains by B of A Securities -- Price Target Raised to $3 - GuruFocus
$Hims & Hers Health (HIMS.US)$ ⸻ $HIMS remains one of the m... - Moomoo
BofA raises Hims and Hers stock price target to $37 on growth - Investing.com Canada
Hims & Hers Health (Ondo Tokenized Stock) Price - Decrypt
Short Seller Who Bet Against Hims & Hers Now Says Its CEO 'Wiped The Floor' With Novo Nordisk - Stocktwits
Hims & Hers Health Options Spot-On: On July 8th, 71,332 Contracts Were Traded, With 958.81K Open Interest - Moomoo
Hims & Hers Health: The Market Still Doesn't Get It - Seeking Alpha
Hims & Hers Expands Benefits for Active Subscribers With Eight New Health and Wellness Partners - AOL.com
I Lost 35 Pounds of Postpartum Weight—Here’s How Hers Helped Me Do It - The Healthy @Reader's Digest
Technical Reactions to HIMS Trends in Macro Strategies - Stock Traders Daily
Here's Why Hims & Hers Health, Inc. (HIMS) Fell More Than Broader Market - Yahoo Finance
Hims & Hers CFO Okupe sells $261k in stock - Investing.com
Form 4 Hims Hers Health Inc For: 7 July By Investing.com - Investing.com Nigeria
Hims & Hers CFO Okupe sells $261k in stock By Investing.com - Investing.com Canada
Hims & Hers (NYSE: HIMS) CFO exercises options and sells 7,163 shares under 10b5-1 plan - Stock Titan
HIMS Stock Slips Overnight After FDA Staff Questions Safety Of Popular Peptides — But One Analyst Says ‘This Isn’t The End’ - Stocktwits
Hims & Hers (HIMS) Stock May Be Undervalued After FDA Peptide Questions - Yahoo Finance
Hims & Hers Health vs. Teladoc Health: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Hims Hers Health Inc (HIMS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.08%
1.61%
자본화:
|
볼륨(24시간):